PARP and PARG inhibitors in cancer treatment
D Slade - Genes & development, 2020 - genesdev.cshlp.org
Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …
genomic instability through radiotherapy and chemotherapy has been a powerful but …
Chemoresistance in pancreatic cancer
S Zeng, M Pöttler, B Lan, R Grützmann… - International journal of …, 2019 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC), generally known as pancreatic cancer (PC),
ranks the fourth leading cause of cancer-related deaths in the western world. While the …
ranks the fourth leading cause of cancer-related deaths in the western world. While the …
Combining epigenetic drugs with other therapies for solid tumours—past lessons and future promise
D Morel, D Jeffery, S Aspeslagh, G Almouzni… - Nature Reviews …, 2020 - nature.com
Epigenetic dysregulation has long been recognized as a key factor contributing to
tumorigenesis and tumour maintenance that can influence all of the recognized hallmarks of …
tumorigenesis and tumour maintenance that can influence all of the recognized hallmarks of …
Clinical epigenetics: seizing opportunities for translation
M Berdasco, M Esteller - Nature Reviews Genetics, 2019 - nature.com
Biomarker discovery and validation are necessary for improving the prediction of clinical
outcomes and patient monitoring. Despite considerable interest in biomarker discovery and …
outcomes and patient monitoring. Despite considerable interest in biomarker discovery and …
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
A mounting body of evidence now indicates that PARP inhibitors have the potential to be
used as a foundation for both monotherapy and combination strategies across a wide …
used as a foundation for both monotherapy and combination strategies across a wide …
Unravelling the biology of SCLC: implications for therapy
Small-cell lung cancer (SCLC) is an aggressive malignancy associated with a poor
prognosis. First-line treatment has remained unchanged for decades, and a paucity of …
prognosis. First-line treatment has remained unchanged for decades, and a paucity of …
Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis
Small cell lung cancer is initially highly responsive to cisplatin and etoposide but in almost
every case becomes rapidly chemoresistant, leading to death within 1 year. We modeled …
every case becomes rapidly chemoresistant, leading to death within 1 year. We modeled …
Functions of thrombospondin-1 in the tumor microenvironment
The identification of thrombospondin-1 as an angiogenesis inhibitor in 1990 prompted
interest in its role in cancer biology and potential as a therapeutic target. Decreased …
interest in its role in cancer biology and potential as a therapeutic target. Decreased …
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Purpose: PARP inhibitors (PARPi) are a novel class of small molecule therapeutics for small
cell lung cancer (SCLC). Identification of predictors of response would advance our …
cell lung cancer (SCLC). Identification of predictors of response would advance our …
[HTML][HTML] Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Poly (ADP-ribose) polymerase inhibitors (PARPIs) kill cancer cells by trapping PARP1 and
PARP2. Talazoparib, the most potent PARPI inhibitor (PARPI), exhibits remarkable …
PARP2. Talazoparib, the most potent PARPI inhibitor (PARPI), exhibits remarkable …